Key Takeaways from the Latest Earnings Call of NEFI

In the most recent earnings call, NEFI showcased strong financial performance while outlining strategic initiatives designed to bolster market penetration and enhance brand awareness. The management emphasized their focus on optimizing operations and engaging with healthcare providers to expand patient access. With a clear roadmap for growth heading into 2026, NEFI is poised to capitalize on its current momentum in the epinephrine auto-injector market.

Financial Performance

For the full year 2025, NEFI reported total revenue of $84.3 million, comprising:

• $72.2 million in U.S. net product revenue, marking the company’s first full year of commercial sales.
• $9.7 million from collaboration agreements.
• $2.4 million in supply revenue from international partnerships.

This revenue stream is a strong indicator of underlying demand and commercial traction, reflecting a significant market penetration and recurring prescription behavior. The company's gross-to-net retention was reported to be in the low to mid-50% range, with expectations of achieving steady-state retention around 50% as coverage broadens and prior authorization requirements decline.

In terms of expenses, R&D expenses reached $13.2 million, primarily driven by product development and clinical trials. Selling, General and Administrative (SGA) expenses were significantly higher at $230.1 million, reflecting intentional investments in commercialization, including direct-to-consumer (DTC) marketing and sales operations. The company plans to expand its sales force from 106 to 150 representatives, focusing on high-impact account management while reallocating existing resources to optimize spending.

Strategic Initiatives

Management highlighted several strategic initiatives aimed at expanding NEFI's market presence:

• Sales Force Expansion: The decision to increase the sales force is driven by insights indicating that frequent engagement with healthcare providers can significantly enhance prescription volume. The company aims for at least three calls per month with key accounts to influence prescribing behaviors.
• Market Access Strategy: NEFI achieved approximately 93% commercial coverage by the end of 2025, including efforts to secure unrestricted Medicaid coverage in eight states. This is critical for ensuring affordability and accessibility for patients, particularly in high-volume states.
• Direct-to-Consumer Campaign: NEFI's DTC efforts have markedly increased brand awareness, with aided awareness rising from 20% before the campaign to 60% today. The campaign focuses on emotional benefits, such as reduced anxiety for parents and greater confidence in administering NEFI, which aligns with the company's broader marketing strategy.
• Get NEFI on Us Program: This initiative aims to facilitate prescriptions for eligible patients without requiring an in-office visit, currently accounting for approximately 10% of prescriptions. The company expects this percentage to grow as awareness increases.

Future Outlook

Looking ahead to 2026, NEFI's management provided optimistic guidance. They reiterated their commitment to operational precision and consistency, with an eye on sustainable growth driven by:

• Continued Commercial Expansion: NEFI plans to maintain its focus on deepening prescriber engagement and expanding access while optimizing capital allocation to enhance operational efficiency.
• Patient Refill Dynamics: Management indicated that they expect meaningful refill activity to begin as early as 2026. They project that the majority of prescriptions will come from new patients, with refills increasing as initial prescriptions start to expire. This dynamic is expected to create a sustainable revenue stream in the long term.
• Integration of DTC and Digital Pathways: The company aims to build a robust base of NEFI patients who renew electronically, enhancing market share and reducing friction in the prescription process as the product matures.

“Our objective is on steady, sustained growth built on tighter workflow integration and disciplined commercial execution,” stated management, emphasizing the importance of aligning awareness with access and prescribing behavior.

Conclusion

In summary, NEFI's recent earnings call illustrated a company in a strong position, focusing on growth and operational efficiency. With impressive revenue figures for 2025 and a strategic plan for 2026 that emphasizes market access, patient engagement, and sales force expansion, NEFI is well-poised for continued success in the competitive landscape of epinephrine auto-injectors. The management's disciplined approach to capital allocation and their commitment to building brand equity indicate a solid foundation for long-term value creation. As NEFI navigates the complexities of the healthcare market, investors can look forward to a year of growth and opportunity.